Health Care Distributors Bi-Weekly Industry Events & M&A Update — September 14–28, 2026

Read the report

SlidesScroll

1 of 7

←→Full screen

BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE

HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › HEALTH CARE DISTRIBUTORS

Product Launches Move Prices While the Deal Record Holds Still

This update covers what moved, what companies announced and what the transaction record showed across Health Care Distributors from September 14–28, 2026.

September 14–28, 2026

Prepared by NeuraCap AI · Confidential

Market data through 2026-09-28 · events and transactions from the two-week period 2026-09-14 → 2026-09-28

Health Care Distributors Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice

Sources & methodology

1

← Previous

1 / 7 · HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › HEALTH CARE DISTRIBUTORS

Next →

What each page shows

The analyst’s walkthrough of the deck, page by page.

1. 01
   BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE

   HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › HEALTH CARE DISTRIBUTORS

   This is the cover page introducing the Health Care Distributors bi-weekly industry events and M&A update for September 14–28, 2026.

   We open this bi-weekly update on Health Care Distributors, covering what changed, who moved and why, what transacted, and what it means for the two weeks ended September 28, 2026. Let's walk through the period's evidence together.

   Everything on this page

   BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › HEALTH CARE DISTRIBUTORS Product Launches Move Prices While the Deal Record Holds Still This update covers what moved, what companies announced and what the transaction record showed across Health Care Distributors from September 14–28, 2026. September 14–28, 2026 Prepared by NeuraCap AI · Confidential Market data through 2026-09-28 · events and transactions from the two-week period 2026-09-14 → 2026-09-28 Health Care Distributors Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 1

2. 02
   THE BI-WEEKLY BOTTOM LINE

   Single-Company News, Not a Sector-Wide Move, Set Prices This Period

   This page summarizes the two-week period in one page, showing that single-company news, not a sector-wide move, set prices across the 8 covered names.

   Six of the eight covered names fell over the period, and the median move was -4.7% against a +0.8% return for the S&P 500 — so this was a company-driven period, not a sector rotation. One approval-driven gain carried the set's only large upside surprise, and the standing 32-deal transaction record held steady at 11.4x EV/EBITDA with no new entries. We'll unpack each of these threads on the following pages, because the details explain where the real signal sits.

   Everything on this page

   THE BI-WEEKLY BOTTOM LINE Single-Company News, Not a Sector-Wide Move, Set Prices This Period The two-week period in one page · 8 covered names, close-to-close · September 14–28, 2026 Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Driver attributions use calibrated language and are NeuraCap reads of the recorded evidence. Health Care Distributors Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 2 1 The Set Gave Ground While the Broad Market Edged Up 6 of 8 covered names fell; the median move was -4.7%. The S&P 500 returned +0.8% over the same window. 2 One Approval Carried the Period's Only Large Gain Amneal Pharmaceuticals, Inc. (AMRX), a Core-tier name, rose +19.0%, with its biggest single session at +8.6%. Shares moved in the same window in which the company announced FDA approval and immediate launch of Lanreotide Injection. 3 The Transaction Record Added Nothing New No material sector transactions were announced during the period. The trailing record of 32 precedent transactions still carries a median of 11.4x EV/EBITDA. 4 The Two-Market Split in the Standing View Held NeuraCap's standing sector view puts the median at 10.4x EV/EBITDA on CY2027E, the Premium tier at 12.6x and the Discount tier at 6.8x. Nothing companies announced over the two-week period challenged that split. +19.0% Best mover — AMRX worst: AVAH -11.8% · 2 up / 6 down of 8 covered -4.7% Sector median two-week return vs S&P 500 +0.8%

3. 03
   PUBLIC MARKET MOVERS

   One Approval Lifts a Core-Tier Name While the Rest of the Set Slips

   This page ranks the period's public market moves close-to-close, showing one FDA approval lifting a Core-tier name while most of the covered set declined.

   Amneal Pharmaceuticals (AMRX) rose +19.0% in the window, with its largest single session at +8.6%, in the same window the company announced FDA approval and immediate launch of Lanreotide Injection. Against that, the sector median move was -4.7%, well inside the ±9.2% materiality bar we use to flag sector-relative moves, while the S&P 500 returned +0.8% over the same period. This divergence tells us the period's pricing came from company-specific catalysts, not a broad re-rating — so where a name lacks a recorded driver, we say so plainly rather than infer one.

   Everything on this page

   PUBLIC MARKET MOVERS One Approval Lifts a Core-Tier Name While the Rest of the Set Slips Bi-Weekly moves, close-to-close · September 14–28, 2026 · sector median -4.7% · S&P 500 +0.8% · materiality bar ±9.2% (sector-relative) Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Attribution links each move only to filings and headlines recorded in the window; where no driver is recorded, the page says so. Calibrated language throughout — NeuraCap reads, not asserted causation. Health Care Distributors Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 3 Bi-Weekly return per company · teal above zero, amber below · sector median -4.7% Amneal Pharmaceuticals, Inc. (AMRX) +19.0% Shares moved following the company's announcement of FDA approval and immediate launch of Lanreotide Injection, a long-acting oncology injectable supported by in-house production. An approved product made in-house adds gross profit dollars, not just units through the channel. COMPANY-SPECIFIC Aveanna Healthcare Holdings Inc. (AVAH) -11.8% No notable in-window news was identified that clearly explains the move. Aveanna Healthcare Holdings Inc. (AVAH) fell -11.8%, a wider decline than the set's median move of -4.7%. Core-tier names can give back ground in a period with no fresh company disclosure to point to. UNEXPLAINED

4. 04
   MAJOR NEWS & INDUSTRY CATALYSTS

   Companies Spent the Period on Product, Brand and the Boardroom

   This page lists the period's highest-impact company events across product, brand and governance, each linked to its underlying source.

   Across the two weeks, the events that mattered most to the covered set concentrated on product approvals, brand investment and boardroom changes rather than sector-wide developments. Each entry links back to the filing or article it is drawn from, and every 'why it matters' read is our own interpretation of that recorded evidence, not the evidence itself. That distinction matters because it lets a client trace every catalyst back to its source before acting on it — so what we present here is traceable, not asserted.

   Everything on this page

   MAJOR NEWS & INDUSTRY CATALYSTS Companies Spent the Period on Product, Brand and the Boardroom The two-week period's highest-impact events · titles link to the underlying filing or article · September 14–28, 2026 Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. "Why it matters" lines are NeuraCap reads; each event links to its source. Sources are admitted in a fixed reliability order (SEC filings, press releases, established outlets); video and social platforms are never used. Health Care Distributors Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 4 Sep 28 · NEWS · GlobeNewsWire Tilray expands BrewDog's senior marketing, hospitality, category and international leadership Commercial leadership hires show where the company expects to push volume and mix next. Where a company puts its commercial talent is a practical signal about which margin pool it is chasing. Leadership additions on the commercial side usually precede a change in channel emphasis. Sep 25 · NEWS · Business Wire Cencora elects Robert E. Sanchez to its board as a new independent director Cencora, Inc. (COR) is adding senior transport and logistics leadership experience at board level. Distribution economics are increasingly a network design question, not only a sourcing question. Sep 23 · NEWS · Business Wire McKesson schedules its second quarter fiscal 2027 results and investor webcast McKesson Corporation (MCK) sets the calendar for the next hard read on gross profit dollars per unit and generic sourcing penetration from a Premium-tier wholesaler. The set's mix and sourcing questions wait for the large platforms' own reporting dates. Sep 22 · NEWS · GlobeNewsWire Tilray puts fresh investment behind BrewDog with an 'Under New Ownership' brand campaign Tilray Brands, Inc. (TLRY), a Discount-tier name, is spending behind an acquired brand rather than integrating it quietly. The read is that own-brand pull, not distribution alone, is the intended return on that purchase. Owned brands only pay back when someone funds the demand side after close. Sep 18 · NEWS · GlobeNewsWire Amneal wins FDA approval and launches Lanreotide Injection, produced in-house A complex injectable made on the company's own lines expands the margin pool rather than the revenue line. That is the kind of mix shift the sector's earnings quality debate turns on. Complex injectables and cold chain capability are where added margin dollars are being sought. Sep 17 · NEWS · GlobeNewsWire Kamada confirms KedRAB supply is sufficient as the CDC reports rising U.S. rabies exposures Kamada Ltd. (KMDA) says it can meet increased utilisation of one of only two FDA-approved anti-rabies immunoglobulin products in the U.S. Fill rate against contract matters most in products with few approved alternatives.

5. 05
   M&A & STRATEGIC ACTIVITY

   No New Transactions: The Standing Record Remains the Reference Set

   This page confirms no new transactions were announced in the period, leaving the standing 32-deal precedent record at a median 11.4x EV/EBITDA as the reference set.

   No material sector transactions were announced across the two weeks, so the reference set for underwriting remains the trailing record of 32 recorded deals at a median 11.4x EV/LTM EBITDA. We do not re-present older transactions as news; when the record doesn't move, we say so directly. For acquirers and advisers, that means current underwriting should still be benchmarked against this standing multiple until a new transaction actually prints.

   Everything on this page

   M&A & STRATEGIC ACTIVITY No New Transactions: The Standing Record Remains the Reference Set September 14–28, 2026 · precedent transactions: 32 recorded deals · median 11.4x EV/LTM EBITDA Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Deal multiples are LTM at announcement where disclosed; "why the deal happened" is a NeuraCap read of the recorded evidence. No old transactions are re-presented as news. Health Care Distributors Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 5 No Material Transactions Announced No material sector transactions were announced during the period. The trailing record of 32 precedent transactions carries a median of 11.4x EV/EBITDA, and that remains the reference point buyers and sellers are working from. A quiet two-week period is information: buyer appetite, financing conditions and seller expectations all read through a period with no new deals. The precedent transactions alongside still frame what buyers have paid. 32 Recorded precedent transactions the reference set buyers and sellers price against 11.4x Precedent median EV/LTM EBITDA LTM at announcement, where disclosed

6. 06
   WHAT IT MEANS

   What a News-Driven Period Changes for Operators, Buyers and Advisers

   This page translates the period's news into implications for operators, acquirers and advisers.

   For owners and operators, the period's news spoke to margin dollars per unit shipped, specialty mix and generic sourcing penetration rather than headline growth. For acquirers, the precedent record didn't move, so underwriting still sits against the same 32 deals at 11.4x EV/EBITDA. For advisers, the story is company-specific — an approval and launch, a supply assurance, a board addition — so the strongest pitch leads with that evidence, not sector-wide drift.

   Everything on this page

   WHAT IT MEANS What a News-Driven Period Changes for Operators, Buyers and Advisers The two-week period translated for the people who act on it · NeuraCap view · observations, not recommendations Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. This page is analytical interpretation drawn from the two-week period's recorded evidence. It is not investment advice. Health Care Distributors Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 6 Sector study 2026-09-28 EV / EBITDA (CY2027E) median 10.4x 9 companies in the study 3 valuation tiers Standing thesis: Health Care Distributors Trades as Two Markets: Scaled Wholesalers and Channel-Adjacent Manufacturers FOR OWNERS & OPERATORS Margin Dollars, Not Headlines, Carried the Period Gross profit dollars per unit shipped, specialty mix as a share of the margin pool and generic sourcing penetration are what the period's news spoke to. FOR ACQUIRERS The Reference Set Did Not Move Nothing new entered the precedent record over the two-week period, so underwriting still sits against 32 prior transactions at a median of 11.4x EV/EBITDA. FOR ADVISORS Lead with Company Evidence, Not Sector Drift The period's story is company-specific: an approval and launch, a supply assurance, a board addition, brand reinvestment.

7. 07
   SOURCES & METHODOLOGY

   Sources, Methodology and Important Notice

   This page explains how the update is built and what each type of statement is sourced from.

   Every figure in this update links back to the underlying filing, press release or price record it was drawn from, and driver attributions are labeled as NeuraCap reads rather than confirmed fact. Sources are drawn from SEC filings, company press releases and established outlets in that order of reliability; video and social platforms are excluded entirely. This structure lets a reader verify any claim against its original record before relying on it — so confidence in the read comes from traceability, not assertion.

   Everything on this page

   SOURCES & METHODOLOGY Sources, Methodology and Important Notice How this bi-weekly update is built and what each kind of statement rests on · September 14–28, 2026 · market data through 2026-09-28 Every figure in this update links to the record it was taken from; the publishers and filings drawn on for the period are listed above. Health Care Distributors Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice 7 OBSERVED DATA Bi-Weekly stock moves are computed close-to-close over the stated window from the platform’s price series. Deal records, values and multiples come from the platform’s transaction record (SEC 8-K extractions) exactly as recorded; each figure links to its citation. Treasury rates come from the platform’s Treasury series and are shown only when the 10-year moved at least ten basis points over the window (it did not in this window, so no rate figures appear). UNIVERSE QUALITY The update universe is the platform’s approved company set for this sector, subject to a $100M market-cap floor so small, loosely related names cannot dominate the statistics. 1 name below the floor was excluded from movers and statistics for this window. EVENTS & NEWS Company events are in-window 8-K filings; news items are publisher-sourced headlines fetched for the window (and any externally supplied items, marked as such). Operational and strategic developments (deals, partnerships, launches, expansion, guidance, leadership, regulatory outcomes) are shown first; capital-return mechanics and conference appearances are limited to one each. Every event links to its source. The deck never asserts an event that has no linked record. SOURCE HIERARCHY News is admitted in a fixed order of reliability: SEC filings first, then company press releases and investor-relations communications, then transaction documents, then established outlets (Reuters, CNBC, The Wall Street Journal, Barron’s and peers). Video and social platforms — including YouTube — are never used as sources. DRIVER ATTRIBUTION A stock move is linked to an event only when the event falls inside the window, and only in calibrated language ("the move appears to reflect…", "shares moved following…"). Where no driver is recorded, the page says so and compares the move to the sector median instead. ANALYTICAL INTERPRETATION "Why it matters", "why the deal happened" and the what-it-means page are NeuraCap analytical views drawn from the recorded evidence, and are labeled as such. INHERITED CONTEXT The standing sector view (thesis, valuation lens, sector median and tiering) is inherited from the NeuraCap sector study run_20260929T161832Z_529_prod (market data as of 2026-09-28) — distilled, never re-derived. That report’s own sources page governs its content; this update reads the period against it. IMPORTANT NOTICE This report is informational only. It is not investment advice, not a recommendation to buy or sell any security, and not an offer of any kind. Readers should perform their own diligence before acting on anything described here. Linked sources this two-week period: globenewswire.com · businesswire.com

More coverage in Health Care

• Sector Report · Sep 28, 2026Health Care Distributors Sector Outlook — September 2026
• Bi-Weekly Update · Sep 28, 2026Medical Devices Bi-Weekly Industry Events & M&A Update — September 14–28, 2026
• Sector Report · Sep 28, 2026Managed Health Care Sector Outlook — September 2026
• Bi-Weekly Update · Sep 28, 2026Managed Health Care Bi-Weekly Industry Events & M&A Update — September 14–28, 2026